The effects of the histone deacetylase inhibitor valproic acid on cell cycle, growth suppression and apoptosis in multiple myeloma
- PMID: 16461312
The effects of the histone deacetylase inhibitor valproic acid on cell cycle, growth suppression and apoptosis in multiple myeloma
Abstract
The aim of this study was to evaluate the effects of valproic acid (VPA), as a histone deacetylase inhibitor, on myeloma cell lines and on sorted human bone marrow multiple myeloma cells. VPA induced accumulation of acetylated histones, potently inhibited proliferation in a dose-dependent manner and induced apoptosis in all myeloma cell lines tested as well as in sorted primary multiple myeloma cells. Cell cycle analysis indicated an arrest in G0/1 phase in response to VPA. Accumulation of p21 and reduced levels of cyclin D1 were detected. The production of vascular endothelial growth factor was significantly inhibited by VPA. These results provide the framework for clinical trials.
Similar articles
-
In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor.Br J Haematol. 2008 Nov;143(4):520-31. doi: 10.1111/j.1365-2141.2008.07387.x. Br J Haematol. 2008. PMID: 18986388
-
Histone deacetylase inhibitor valproic acid inhibits proliferation and induces apoptosis in KM3 cells via downregulating VEGF receptor.Neuro Endocrinol Lett. 2007 Dec;28(6):775-80. Neuro Endocrinol Lett. 2007. PMID: 18063935
-
Multiple Molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo.Prostate. 2007 Jul 1;67(10):1099-110. doi: 10.1002/pros.20587. Prostate. 2007. PMID: 17477369
-
Valproic acid for the treatment of myeloid malignancies.Cancer. 2007 Sep 1;110(5):943-54. doi: 10.1002/cncr.22891. Cancer. 2007. PMID: 17647267 Review.
-
Evolving anticancer drug valproic acid: insights into the mechanism and clinical studies.Med Res Rev. 2005 Jul;25(4):383-97. doi: 10.1002/med.20027. Med Res Rev. 2005. PMID: 15637697 Review.
Cited by
-
Valproic acid upregulates NKG2D ligand expression and enhances susceptibility of human renal carcinoma cells to NK cell-mediated cytotoxicity.Arch Med Sci. 2013 Apr 20;9(2):323-31. doi: 10.5114/aoms.2013.34413. Epub 2013 Apr 9. Arch Med Sci. 2013. PMID: 23671445 Free PMC article.
-
Inhibitory effect of valproic acid on bladder cancer in combination with chemotherapeutic agents in vitro and in vivo.Oncol Lett. 2013 Nov;6(5):1492-1498. doi: 10.3892/ol.2013.1565. Epub 2013 Sep 6. Oncol Lett. 2013. PMID: 24179547 Free PMC article.
-
Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitors.Br J Cancer. 2013 Aug 6;109(3):676-85. doi: 10.1038/bjc.2013.392. Epub 2013 Jul 18. Br J Cancer. 2013. PMID: 23868005 Free PMC article.
-
The combination of HDAC and aminopeptidase inhibitors is highly synergistic in myeloma and leads to disruption of the NFκB signalling pathway.Oncotarget. 2015 Jul 10;6(19):17314-27. doi: 10.18632/oncotarget.1168. Oncotarget. 2015. PMID: 26015393 Free PMC article.
-
Anti-Epileptic Drug Targets Ewing Sarcoma.J Pharm Sci Pharmacol. 2014 Jun 1;1(2):87-100. doi: 10.1166/jpsp.2014.1013. J Pharm Sci Pharmacol. 2014. PMID: 25664332 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials